QLT Photofrin lung cancer promotions to begin in second quarter; FDA clears narrow new indication.
Executive Summary
QLT PHOTOFRIN LUNG CANCER PROMOTIONS TO BEGIN IN SECOND QUARTER 1998, following FDA clearance Jan. 9 for the photodynamic treatment of microinvasive non-small cell lung cancer. Photofrin is marketed in the U.S. by Sanofi for palliation of obstructing esophageal cancer. The supplemental indication, while narrow, gives QLT a position in the lung cancer therapy market. Photofrin (photodynamic porfimer) is now indicated "for use in photodynamic therapy for the treatment of microinvasive endobronchial non-small cell lung cancer in patients for whom surgery and radiotherapy are not indicated," labeling states.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth